{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:52:07Z","timestamp":1785333127201,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ijantimicag.2017.06.016","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T19:45:34Z","timestamp":1499715934000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Empiric antibiotic protocols for cancer patients with neutropenia: a single\u2013center study of treatment efficacy and mortality in patients with bacteremia"],"prefix":"10.1016","volume":"51","author":[{"given":"Eyal","family":"Kleinhendler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matan J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allon E.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Strahilevitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Cahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0010","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamainternmed.2013.2921","article-title":"Deviations from guideline\u2013based therapy for febrile neutropenia in cancer patients and their effect on outcomes","volume":"173","author":"Wright","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1086\/513764","article-title":"1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America","volume":"25","author":"Hughes","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.1971.03190140038007","article-title":"Carbenicillin therapy for pseudomonas infections","volume":"218","author":"Bodey","year":"1971","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0030","first-page":"1","article-title":"Performance standards for antimicrobial susceptibility testing, 23rd informational supplement (M100-S23)","volume":"33","author":"CLSI","year":"2013","journal-title":"Clin Lab Stand Inst"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0045","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2334-14-161","article-title":"Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijantimicag.2012.12.006","article-title":"\u03b2-Lactam plus aminoglycoside or fluoroquinolone combination versus \u03b2-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis","volume":"41","author":"Vardakas","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/AAC.02235-12","article-title":"Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia","volume":"57","author":"Bowers","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0080","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","article-title":"Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria","volume":"29","author":"Zinner","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-2727.163126","article-title":"Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients","volume":"7","author":"Lakshmaiah","year":"2015","journal-title":"Lab Physicians"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jinf.2014.05.018","article-title":"Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours","volume":"69","author":"Marin","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1556\/1886.2015.00021","article-title":"Evaluation of bloodstream infections during chemotherapy-induced febrile neutropenia in patients with malignant hematological diseases: single center experience","volume":"5","author":"Piukovics","year":"2015","journal-title":"Eur J Microbiol Immunol"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1472-6963-14-162","article-title":"Time to antibiotics and outcomes in cancer patients with febrile neutropenia","volume":"14","author":"Perron","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijantimicag.2012.05.001","article-title":"Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients","volume":"40","author":"Ram","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00134-013-3077-7","article-title":"De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock","volume":"40","author":"Garnacho-Montero","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0120","first-page":"Doc14","volume":"8","author":"Reinhart","year":"2010","journal-title":"Ger Med Sci"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0125","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cmi.2014.10.014","article-title":"Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical","volume":"21","author":"Orasch","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0130","series-title":"Carbapenemase-producing bacteria in Europe: interim results from the European Survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project","author":"European Centre for Disease Prevention and Control","year":"2013"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","article-title":"Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe","volume":"18","author":"Canton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0140","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1128\/AAC.02756-15","article-title":"KPC-Like carbapenemase-producing Enterobacteriaceae colonizing patients in Europe and Israel","volume":"60","author":"Baraniak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.016_bib0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.diagmicrobio.2016.04.002","article-title":"Prevalence and risk factors for carriage of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae among patients prior to bowel surgery","volume":"85","author":"Pfeffer","year":"2016","journal-title":"Diagn Microbiol Infect Dis"}],"updated-by":[{"DOI":"10.1016\/j.ijantimicag.2023.106928","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T20:28:13Z","timestamp":1694118493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0924857917302650"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.016","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ijantimicag.2023.106928","asserted-by":"object"}]},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empiric antibiotic protocols for cancer patients with neutropenia: a single\u2013center study of treatment efficacy and mortality in patients with bacteremia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}